title: Reduction of immune system activation in HIV-1-infected patients undergoing highly active antiretroviral therapy.
abstract: The aim of this work was to analyze the effects of highly active antiretroviral therapy on the chronically activated immune system of 26 antiretroviral-naive HIV-1-infected patients. Samples from baseline to week 24 or 36 of treatment were tested for serum levels of beta2-microglobulin, tumor necrosis factor alpha and soluble tumor necrosis factor alpha receptor type II, as well as for human leukocyte antigen-DR expression on T cells. After starting therapy, the mean HIV-1 RNA serum levels decreased and the mean CD4 + cell counts increased from baseline to week 36 (P< 0.001). Mean levels of tumor necrosis factor alpha receptor type II, tumor necrosis factor alpha and beta2-microglobulin as well as expression of human leukocyte antigen-DR were significantly reduced at the end of follow-up (P<0.01). Deactivation kinetics of these parameters was similar in patients with CD4+ counts>200 cells/microl at baseline versus those with CD4 + counts < 200 cells/microl at baseline, despite higher activation at baseline in the group with <200 cells/microl. In summary, this study shows that highly active antiretroviral therapy is able to induce a strong deactivation of the immune system of HIV-1-infected patients.
authors.affiliation: Department of Internal Medicine, Virgen del Rocío University Hospital, Seville, Spain. mleal@cica.es
authors.forename: J M
authors.initials: JM
authors.lastname: Franco
authors.forename: A
authors.initials: A
authors.lastname: Rubio
authors.forename: C
authors.initials: C
authors.lastname: Rey
authors.forename: M
authors.initials: M
authors.lastname: Leal
authors.forename: J
authors.initials: J
authors.lastname: Macías
authors.forename: J A
authors.initials: JA
authors.lastname: Pineda
authors.forename: B
authors.initials: B
authors.lastname: Sánchez
authors.forename: A
authors.initials: A
authors.lastname: Sánchez-Quijano
authors.forename: A
authors.initials: A
authors.lastname: Nuñez-Roldán
authors.forename: E
authors.initials: E
authors.lastname: Lissen
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015703:Antigens, CD / Q000097:blood; D005260:Female; D015497:HIV-1; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D001613:beta 2-Microglobulin / Q000097:blood
chemical_list: D019380:Anti-HIV Agents; D015703:Antigens, CD; D006684:HLA-DR Antigens; D018124:Receptors, Tumor Necrosis Factor; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha; D001613:beta 2-Microglobulin